The Palmoplantar Psoriasis Global Assessment (PPPGA) is a physician-administered tool used to assess the severity of palmoplantar psoriasis, primarily affecting the hands and feet. This evaluation is essential in determining treatment approaches and monitoring the disease’s impact on a patient’s quality of life.
The PPPGA rates psoriasis severity on a scale from 0 to 4 based on erythema (redness), scaling, and the presence of pustules and fissures:
Reference
Apremilast, An Oral Phosphodiesterase-4 Inhibitor, in the Treatment of Palmoplantar Psoriasis: Results of a Pooled Analysis from Phase II PSOR-005 and Phase III ESTEEM Clinical Trials in Patients with Moderate to Severe Psoriasis. Bissonnette R, Pariser DM, Wasel NR, et al. J Am Acad Dermatol. 2016;75:99-105.
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
